Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial
Citations:15
Influential Citations:0
Interventional (Human) Studies
86
Enhanced Details
Methods
Seventy-six obese patients with NAFLD were randomized to receive either 250 mg of OEA or a placebo for 12 weeks, while following a weight loss diet.
Intervention
The trial evaluated the effects of oleoylethanolamide (OEA) supplementation alongside a weight loss intervention in patients with nonalcoholic fatty liver disease (NAFLD).
Results
OEA supplementation led to significant improvements in several atherogenic indices, including reduced LDL-C/HDL-C, TG/HDL-C, and non-HDL-C/HDL-C ratios. It also decreased red blood cell distribution width (RDW) compared to the placebo group.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world. The current interventional trial aimed to evaluate the effects of supplementation with oleoylethanolamide (OEA) in combination wit...